Completed PHASE2 INTERVENTIONAL NCT00184080

Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Non-Hodgkin's Lymphoma

Interventions Elsamitrusin

Updated 7 times since 2017 Last updated: May 20, 2014 Started: May 31, 2004 Primary completion: Apr 30, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-Hodgkin's Lymphoma and is currently completed. Spectrum Pharmaceuticals, Inc leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spectrum Pharmaceuticals, Inc
University of Southern California

Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States